ArticleCancer chemotherapy and pharmacology2025

Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial.

Yizhe Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.